摘要
目的探讨奥沙利铂联合希罗达用于结直肠癌术后患者的安全性及疗效。方法选择108例原发性结直肠癌术后患者,按照术后化疗方案的不同分为实验组与对照组,对照组仅采用希罗达治疗,实验组则在对照组的基础上联合奥沙利铂治疗。比较2组患者的生存率、复发率、远处转移率、不良反应及生存质量Karnofsky评分情况。结果实验组2年生存率为96.43%,显著高于对照组84.62%;实验组复发率、远处转移率为10.71%、35.71%,显著低于对照组17.31%、44.23%,比较差异均具有统计学意义(P<0.05)。实验组腹泻、神经毒性、手足综合征、皮肤色素沉着、白细胞减少及恶心呕吐等不良反应与对照组比较,差异均无统计学意义(P>0.05)。治疗后2组患者Karnofsky评分均有所降低,组间比较差异无统计学意义(P>0.05);治疗后6个月实验组Karnofsky评分升高明显,显著优于对照组,比较差异具有统计学意义(P<0.05)。结论奥沙利铂联合希罗达用于结直肠癌术后患者辅助化疗能够延长患者生存时间,减少局部复发率及远处转移率,提高患者生存质量,并且具有较高的安全性。
Objective To investigate the safety and efficacy effect of oxaliplatin and xeloda for colorectal cancer after surgery. Methods 108 cases of primary colorectal cancer patients after surgery, according to postoperative chemotherapy regimen were divided into the experimental group and the control group, the control group was only treated with xeloda, the experimental group on the basis of the control group received oxaliplatin treatment, recurrence rates, distant metastasis rates, adverse reactions and quality of fife of Karnofsky score of the 2 groups were compared. Results 2-years survival rate of the experimental group was 96.43%, which was significantly higher than that of the control group, 84.62% ;the recurrence rate and distant metastases rate of the experimental group were 10.71% and 35.71% , which were significantly lower than the control group, 17.31% and 44.23 % （ P 〈 0.05 ）. There were no significant differences in the adverse effects such as diarrhea, neurotoxicity, hand foot syndrome, skin pigmentation, white blood cell reduction and nausea and vomiting between the 2 groups （ P 〉 0.05 ）. After treatment, Karnofsky score of the 2 group patients were all decreased, the difference between the 2 groups had no statistical significance （P 〉 0.05 ） ,6 months after the treatment, Karnofsky score of the experimental group increased significantly, which was significantly better than the control group, the difference had statistical significance（P 〈 0.05 ）. Conclusion 0xaliplatin combined with xeloda in adju- vant chemotherapy for colorectal cancer after resection can prolong the survival time of the patients, reduce the local recurrence rate and distant metastasis rate, and improve the quality of life of the patients, and has higher security.
出处
《实用癌症杂志》
2017年第8期1331-1333,共3页
The Practical Journal of Cancer
关键词
奥沙利铂
希罗达
结直肠癌
术后辅助化疗
安全性
疗效
Oxaliplatin
Xeloda
Colorectal cancer
Postoperative adjuvant chemotherapy
Security
Efficacy
